Tetanus toxoid adsorbed vaccine

Generic Medicine Info
Indications and Dosage
Prophylaxis of tetanus in wound management
Adult: Consider the immunisation status of the patient and the type and condition of the wound. Non-immunised or partially immunised patients, uncertain vaccination history; completely immunised and >10 years since last booster dose: 0.5 mL (≥40 IU) to be given immediately. Completely immunised patients with minor, clean wounds who have been vaccinated within the last 5-10 years may not need a prophylaxis dose. Non-immunised or partially immunised patients or those with uncertain vaccination history are recommended to start and complete a primary series. Refer to detailed product or local treatment guidelines for specific dosing recommendations.

Active immunisation against tetanus
Adult: As ≥40 IU/0.5 mL preparation: Primary immunisation: 0.5 mL for 2 doses, given 4-8 weeks apart, followed by a 3rd dose of 0.5 mL 6-12 months after the 2nd dose. Booster dose: 0.5 mL every 10 years. For neonatal tetanus prophylaxis in pregnant women, the 1st dose is preferably administered ≥90 days prior to birth.
Child: Neonates, infants, children, and adolescents Primary immunisation: Same as adult dose. Treatment recommendations may vary per country; refer to local product guidelines and paediatric vaccine schedules for specific recommendations.
Hypersensitivity. Neurological disorder following a previous dose of vaccine.
Special Precautions
Patient with bleeding disorders (including thrombocytopenia) or vitamin K deficiency, history of respiratory immaturity. Patient who developed Guillain-Barre syndrome within 6 weeks of receiving tetanus toxoid-containing vaccine. Defer immunisation in patients with acute infection or febrile illness; vaccination may be given in patients with mild acute illness (with or without fever). Consider delaying vaccination in patients with severe immunosuppression (e.g. receiving chemotherapy/radiation therapy or high-dose corticosteroids) until the end of the treatment; vaccination in patients with chronic immunosuppression (e.g. HIV infection) is recommended. Avoid vaccination more frequently than every 10 years in patients who have experienced Arthus-type hypersensitivity reaction following vaccination of tetanus toxoid. Patient receiving anticoagulant therapy. Very premature infants (born ≤28 weeks of gestation); infants and children (particularly if with neurological disease, history of febrile seizure, or cerebral damage). Pregnancy and lactation.
Adverse Reactions
Significant: Anaphylactoid or hypersensitivity reactions (including Arthus-type hypersensitivity), syncope, Guillain-Barre syndrome, brachial neuritis.
Blood and lymphatic system disorders: Lymphadenopathy, thrombocytopenia.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. inflammation, warm sensation, pain, rash, induration, oedema; nodules which may develop into aseptic abscess), transient fever, malaise, irritability.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Apnoea (particularly in very premature infants).
Skin and subcutaneous tissue disorders: Urticaria, erythema nodosum, generalised pruritus, rash.
Vascular disorders: Hypotension.
IM/Parenteral/SC: C
Monitoring Parameters
Monitor for hypersensitivity reaction and syncope for at least 15 minutes post-vaccination.
Drug Interactions
May decrease therapeutic effect with immunosuppressants. Risk of haematoma or bleeding following IM inj in patients receiving anticoagulant therapy.
Mechanism of Action: Tetanus toxoid adsorbed vaccine is a preparation of inactivated toxin produced by virulent tetanus bacilli (detoxified growth product of Clostridium tetani). It acts as an antigen and produces active immunity against tetanus.
Duration: Immunity: Approx 10 years.
Store between 2-8°C. Protect from light. Do not freeze. Opened multidose vials may be stored for up to 4 weeks under appropriate cold chain conditions.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AM01 - tetanus toxoid ; Belongs to the class of tetanus bacterial vaccines.
Anon. Tetanus Toxoid (Adsorbed). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/08/2022.

Buckingham R (ed). Tetanus Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/08/2022.

Tetana, Suspension for Injection (Bionovel Co., Ltd). MIMS Thailand. http://www.mims.com/thailand. Accessed 10/08/2022.

Tetanus Toxoid Vaccine Adsorbed (SM Pharmaceuticals Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/08/2022.

Tetanus Toxoid. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 16/08/2022.

Tetanus: For Clinicians. Centers for Disease Control and Prevention. https://www.cdc.gov. Accessed 16/08/2022.

Tetavax Single Dose, Suspension for Injection in a Prefilled Syringe (Sanofi-Aventis Singapore Pte Ltd). MIMS Singapore. http://www.mims.com/singapore. Accessed 10/08/2022.

Disclaimer: This information is independently developed by MIMS based on Tetanus toxoid adsorbed vaccine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • Tetavax
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in